SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001144204-19-037252
Filing Date
2019-08-01
Accepted
2019-08-01 17:05:47
Documents
5
Period of Report
2019-09-12
Effectiveness Date
2019-08-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A tv526060-def14a.htm DEF 14A 809084
2 GRAPHIC lg_outlook-therapeutics.jpg GRAPHIC 118858
3 GRAPHIC tv526060_pc1.jpg GRAPHIC 609352
4 GRAPHIC tv526060_pc2.jpg GRAPHIC 495143
5 GRAPHIC tv526060_pc3.jpg GRAPHIC 763433
  Complete submission text file 0001144204-19-037252.txt   3546784
Mailing Address 7 CLARKE DRIVE CRANBURY NJ 08512
Business Address 7 CLARKE DRIVE CRANBURY NJ 08512 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37759 | Film No.: 19993495
SIC: 2836 Biological Products, (No Diagnostic Substances)